Novogenia AG (MUN:7V0)

Germany · Delayed Price · Currency is EUR

5.80

-0.70 (-10.77%)

At close: Aug 19, 2026

-12.12% (1Y)

Market Cap	69.60M -12.1%
Revenue (ttm)	54.30M -59.2%
Net Income	545.47K -97.7%
EPS	0.05 -97.7%
Shares Out	12.00M
PE Ratio	127.60
Forward PE	n/a
Dividend	0.56 (9.70%)
Ex-Dividend Date	Jun 29, 2026

Volume	300
Open	6.45
Previous Close	6.50
Day's Range	5.80 - 6.45
52-Week Range	5.70 - 11.80
Beta	0.31
Analysts	Strong Buy
Price Target	19.38 (+234.14%)
Earnings Date	Sep 8, 2026

About Novogenia AG

Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing. The company was formerly known as Darwin AG and changed its name to Novogenia AG in June 2026. The company was incorporated in 2021 and is based in Munich, Germany. [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2021

Employees 204

Stock Exchange Munich Stock Exchange

Ticker Symbol 7V0

Full Company Profile

Financial Performance

In 2025, Novogenia AG's revenue was 54.30 million, an increase of 98.53% compared to the previous year's 27.35 million. Earnings were 545,469, a decrease of -97.04%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 7V0 stock is "Strong Buy." The 12-month stock price target is €19.38, which is an increase of 234.14% from the latest price.

Price Target

€19.38

(234.14% upside)

Analyst Consensus: Strong Buy

Stock Forecasts